SMBC Venture Capital

Founded 2005


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 315
Average round size
The average size of a deal this fund participated in
Portfolio companies 299
Rounds per year 19.69
Lead investments 8
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 46
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Internet
  • Software
  • Information Technology
  • Health Care
  • Biotechnology

SMBC Venture Capital appeared to be the VC, which was created in 1992. The company was established in Asia in Japan. The main department of described VC is located in the Chuo.

Opposing the other organizations, this SMBC Venture Capital works on 21 percentage points less the average amount of lead investments. The fund is constantly included in 7-12 deals per year. The top amount of exits for fund were in 2016. When the investment is from SMBC Venture Capital the average startup value is 100-500 millions dollars. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 17 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 5 - 10 millions dollars.

Among the most successful fund investment fields, there are Mobile, Biotechnology. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Base, GROOVE X, BizReach. For fund there is a match between the location of its establishment and the land of its numerous investments - Japan. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the SMBC Venture Capital, startups are often financed by Nissay Capital, Innovation Network Corporation of Japan, Nippon Venture Capital. The meaningful sponsors for the fund in investment in the same round are YJ Capital, NEC Capital Solutions, Mitsui Sumitomo Insuarance Venture Capital. In the next rounds fund is usually obtained by SBI Investment, Innovation Network Corporation of Japan, DBJ Capital.

Besides them, we counted 1 critical employee of this fund in our database.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$3M23 Mar 2021 Chiyoda, Japan


Health Care
$19M12 Mar 2021 Chiyoda, Japan


Information Technology
$900K09 Mar 2021 Japan, Fukuoka Prefecture, Japan

Cardio Intelligence

Artificial Intelligence
Health Care
Information Technology
Machine Learning
$1M02 Mar 2021 Chiyoda, Japan


Supply Chain Management
Taxi Service
$2M21 Feb 2021 Chiyoda, Japan


Personal Health
$6M16 Feb 2021 Tsukuba, Ibaraki Prefecture, Japan


Artificial Intelligence
Information Technology
Internet of Things
$3M15 Jan 2021 Japan, Chiyoda

Financial Services
22 Dec 2020 Chiyoda, Japan


Information Technology
Task Management
$11M05 Dec 2020 Japan, Chiyoda
News aggregator SmartNews raises $230 million, valuing its business at $2 billion

– SmartNews, a news aggregation website and app, raised $230m in Series F funding.
– The round was led by Princeville Capital and Woodline Partners, and joined by JIC Venture Growth Investments, Green Co-Invest Investment, and Yamauchi-No.10 Family Office in Japan.
– Existing investors participated in this round including ACA Investments and SMBC Venture Capital.
– The company plans to develop more features for its U.S. audience that will focus on consumer health and safety.

Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure

– Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.
– New investors are UTokyo Innovation Platform Co. (UTokyo IPC), Medical Incubator Japan, Keio Innovation Initiative (KII), and Sumitomo Mitsui Trust Investment. Among the existing investors, SBI Group, Nissay Capital, SMBC Capital, Medipal Holdings, and Itochu Chemical Frontier participated in this round.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent SMBC Venture Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: